touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache.
The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What is the rationale for using intranasal ketamine in the acute treatment of refractory headache? (0:21)
- Could you tell us a little about your retrospective study and its patient population? (1:10)
- What were the study efficacy and safety findings? (2:57)
- What is the ideal dosing of intranasal ketamine in adults? (4:40)
- Who is likely to benefit most from intranasal ketamine and in whom is it contraindicated? (6:02)
Disclosures: Within the past 24 months, Michael Marmura has received compensation for consultation from Alder/Lumbeck, Lilly, Supernus, and Theranica; has participated in speaker bureaus for Eli Lilly, and Amgen/Novartis; has received institutional support for serving as principal investigator from Teva, GammaCore and Allergan/AbbVie; and has received payments for authorship or royalties from Demos Medical, Cambridge University Press and MedLink.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine
We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]
Richard Lipton, AHS 2021: COURAGE Study Results
touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application. The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!